Influence of pH on the antimicrobial activity of clarithromycin and 14-hydroxyclarithromycin against Haemophilus influenzae using an in vitro pharmacodynamic model

被引:9
作者
Garrison, MW
Malone, CL
Eiland, J
Anderson, DE
机构
[1] DEACONESS MED CTR,SPOKANE,WA
[2] SACRED HEART MED CTR,DEPT MICROBIOL,SPOKANE,WA
关键词
D O I
10.1016/S0732-8893(97)00026-6
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Clarithromycin activity can be influenced by the pH of the surrounding environment. Evidence supports a reduced pH of middle ear fluid (MEF) and lung tissues in patients with otitis media and pneumonia, respectively. To evaluate the influence of pH on clarithromycin activity, an in vitro pharmacodynamic chamber model (PDCM) was used to generate bacterial time-kill curves for clarithromycin and a 2:1 ratio of clarithromycin and 14-hydroxyclarithromycin (HC) against Haemophilus influenzae at three different pH values: 7.2, 6.8, 6.4. Concentrations observed in MEF and lung tissues were simulated for clarithromycin alone and clarithromycin plus HC. Differences in activity at each pH were identified by com paring initial kill curve slopes and total log reduction. Experiments with amoxicillin-clavulanate were conducted as a reference. In simulated MEF regimens at pH 7.2, activity of clarithromycin alone improved by adding HC (additional 2 log(10) reduction at 8 h); however, at pH values of 6.8 and 6.4, kill curves resembled growth controls. In simulated lung regimens, differences between clarithromycin alone and clarithromycin plus HC were insignificant; both produced a 2 log(10) reduction at pH 7.2, and activity dramatically dropped to <0.4 log(10) as pH declined. In contrast, amoxicillin-clavulanate consistently produced a 3 log(10) reduction over each pH value with more rapid initial kill relative to all clarithromycin regimens. These findings suggest the activity of clarithromycin against H. influenzae may be significantly compromised in respiratory tract infections involving a reduced pH. Trials with emphasis on clinical outcomes analysis will assist further in determining the significance of these experimental findings. (C) 1997 Elsevier Science Inc.
引用
收藏
页码:139 / 145
页数:7
相关论文
共 25 条
[1]   INVITRO ACTIVITIES OF AZITHROMYCIN (CP-62,993), CLARITHROMYCIN (A-56268-TE-031), ERYTHROMYCIN, ROXITHROMYCIN, AND CLINDAMYCIN [J].
BARRY, AL ;
JONES, RN ;
THORNSBERRY, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (05) :752-754
[2]   ENDOBRONCHIAL PH - RELEVANCE TO AMINOGLYCOSIDE ACTIVITY IN GRAM-NEGATIVE BACILLARY PNEUMONIA [J].
BODEM, CR ;
LAMPTON, LM ;
MILLER, DP ;
TARKA, EF ;
EVERETT, ED .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1983, 127 (01) :39-41
[3]  
Bryant RE., 1984, New dimensions fo antimicrobial therapy, P313
[4]  
CHAPINROBERTSON K, 1991, ANTIBIOTICS LAB MED, P313
[5]   SIMULTANEOUS DETERMINATION OF CLARITHROMYCIN AND 14(R)-HYDROXYCLARITHROMYCIN IN PLASMA AND URINE USING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION [J].
CHU, SY ;
SENNELLO, LT ;
SONDERS, RC .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1991, 571 (1-2) :199-208
[6]   INVITRO AND INVIVO EVALUATION OF A-56268 (TE-031), A NEW MACROLIDE [J].
FERNANDES, PB ;
BAILER, R ;
SWANSON, R ;
HANSON, CW ;
MCDONALD, E ;
RAMER, N ;
HARDY, D ;
SHIPKOWITZ, N ;
BOWER, RR ;
GADE, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 30 (06) :865-873
[7]   CLARITHROMYCIN CLINICAL PHARMACOKINETICS [J].
FRASCHINI, F ;
SCAGLIONE, F ;
DEMARTINI, G .
CLINICAL PHARMACOKINETICS, 1993, 25 (03) :189-204
[8]   COMPARATIVE ACTIVITY OF TEMAFLOXACIN, OFLOXACIN, AND CIPROFLOXACIN AGAINST STREPTOCOCCUS-PNEUMONIAE USING AN IN-VITRO PHARMACODYNAMIC MODEL APPARATUS [J].
GARRISON, MW ;
CAMPBELL, DM ;
SCLAR, DA ;
ANDERSON, DE .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1994, 55 (12) :1432-1441
[9]   ASSESSMENT OF EFFECTS OF PROTEIN-BINDING ON DAPTOMYCIN AND VANCOMYCIN KILLING OF STAPHYLOCOCCUS-AUREUS BY USING AN INVITRO PHARMACODYNAMIC MODEL [J].
GARRISON, MW ;
VANCEBRYAN, K ;
LARSON, TA ;
TOSCANO, JP ;
ROTSCHAFER, JC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (10) :1925-1931
[10]   OVERVIEW OF THE PHARMACOLOGY OF CLARITHROMYCIN SUSPENSION IN CHILDREN AND A COMPARISON WITH THAT IN ADULTS [J].
GUAY, DRP ;
CRAFT, JC .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1993, 12 (12) :S106-S111